-
Mashup Score: 2Targeting KRAS in cancer - 21 day(s) ago
Nature Medicine – Recent developments in bioengineering and organic chemistry have enabled targeting of the previously ‘undruggable’ KRAS; this review summarizes the successes,…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Validate User - 1 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
Invasive cancers typically evade immune surveillance through profound local and systemic immunosuppression, preventing their elimination or control. Targeting immune interventions to prevent or intercept premalignant lesions, before significant immune dysregulation has occurred, may be a more successful strategy. The field of cancer immune interception and prevention is nascent, and the scientific community has been slow to embrace this potentially most rational approach to reducing the global burden of cancer. This may change due to recent promising advances in cancer immunoprevention including the use of vaccines for the prevention of viral cancers, the use of cancer-associated antigen vaccines in the setting of precancers, and the development of cancer-preventative vaccines for high-risk individuals who are healthy but carry cancer-associated heritable genetic mutations. Furthermore, there is increasing recognition of the importance of cancer prevention and interception by national
Source: jitc.bmj.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Targeting ATR in patients with cancer - 3 month(s) ago
Nature Reviews Clinical Oncology – Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) is a mediator of the cellular replication stress response that, upon activation,…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Unveiling the mechanisms and challenges of cancer drug resistance - Cell Communication and Signaling - 3 month(s) ago
Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer treatment strategies are evolving due to innate and acquired resistance capacity, governed by genetic, epigenetic, proteomic, metabolic, or microenvironmental cues that ultimately enable selected cancer cells to survive and progress under unfavorable conditions. Although the mechanism of drug resistance is being widely studied to generate new target-based drugs with better potency than existing ones. However, due to the broader flexibility in acquired drug resistance, advanced therapeutic options with better efficacy need to be explored. Combination therapy is an alternative with a better success rate though the risk of amplified side effects is commonplace. Moreover, recent groundbreaking precision immune therapy is one of the ways to overcome drug resistance and has revolutionized anticancer therapy to a greater extent with the only limitation of being individual-specific and needs further attention. Th
Source: biosignaling.biomedcentral.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting - 4 month(s) ago
High microsatellite instability (MSI-H) derives from genomic hypermutability due to deficient mismatch repair function. Colorectal (CRC) and endometrial cancers (EC) are the tumor types that more often present MSI-H. Anti-PD(L)-1 antibodies have been demonstrated to be agnostically effective in patients with MSI-H cancer, but 50–60% of them do not respond to single-agent treatment, highlighting the necessity of expanding their treatment opportunities. Ipilimumab (anti-CTLA4) is the only immune checkpoint inhibitor (ICI) non-targeting PD(L)-1 that has been approved so far by the FDA for MSI-H cancer, namely, CRC in combination with nivolumab. Anti-TIM3 antibody LY3321367 showed interesting clinical activity in combination with anti-PDL-1 antibody in patients with MSI-H cancer not previously treated with anti-PD(L)-1. In contrast, no clinical evidence is available for anti-LAG3, anti-TIGIT, anti-BTLA, anti-ICOS and anti-IDO1 antibodies in MSI-H cancers, but clinical trials are ongoing. O
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Exploring the next generation of antibody–drug conjugates - 4 month(s) ago
Nature Reviews Clinical Oncology – Antibody–drug conjugates (ADCs) are effective cancer drugs that have been approved for more than 20 specific indications. Nonetheless, acquired resistance…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome - Nature Reviews Drug Discovery - 4 month(s) ago
T cell receptors (TCRs) enable the targeting of proteins selectively expressed by cancer cells, including neoantigens, cancer germline antigens and viral oncoproteins. This Review discusses the current cancer treatment landscape using TCRs and TCR-like molecules, including adoptive cell transfer of T cells expressing endogenous or engineered TCRs or TCR bispecific engagers.
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Nature Reviews Drug Discovery – This Review discusses the mechanisms that regulate stabilization of hypoxia-inducible factors (HIFs), and the pharmacological strategies to activate or inhibit HIFs…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies - 5 month(s) ago
Signal Transduction and Targeted Therapy – Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Targeting KRAS in Cancer https://t.co/yFdsGa8tbA https://t.co/QSV0X6qyRN